Results 111 to 120 of about 78,599 (168)

Referral delays in metastatic breast cancer care: barriers and facilitators across a fragmented pathway. [PDF]

BMJ Open Qual
Peerawong T, Phenwan T, Supanichwatana S, Siammai N, Sunthorn P, Gray NM.   +5 more
europepmc   +1 more source

Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024. [PDF]

Breast Cancer Res Treat
Meisel JL, Chen C, Kris A, Ru M, Pham T, Roose J.   +5 more
europepmc   +1 more source

Eco-Evolutionary Thinking in Metastatic Breast Cancer: A Clinician's Primer on Why Tumors Outsmart Us and How to Fight Back Smarter. [PDF]

Cancers (Basel)
Soyano AE, Brady-Nicholls R, Soliman HH, Gatenby RA, Robertson-Tessi M, Ataya D.   +5 more
europepmc   +1 more source

Antibacterial Activity of Essential Oils as Phytotherapeutic Alternatives Against <i>Aeromonas</i> spp. from Ornamental Fish. [PDF]

Pathogens
Seçer FS.
europepmc   +1 more source

Primary Surgery in Metastatic Breast Cancer. [PDF]

Eur J Breast Health
Balcı E, Maden AS, Eryilmaz MA.
europepmc   +1 more source

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer with severe hepatic dysfunction: a case report and narrative literature review. [PDF]

Front Oncol
Saltalamacchia G, Gerosa R, Canzian J, Benvenuti C, Giannitto C, Jacobs F, Gaudio M, Tinterri B, Miggiano C, Masci G, De Sanctis R, Torrisi R, Santoro A.   +12 more
europepmc   +1 more source

Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France. [PDF]

Breast
Frenel J, de Nonnevile A, Guerin-Charbonnel C, Zeghondy J, Mathiot L, Mailliez A, Poumeaud F, Isambert N, Arnedos M, Le Du F, Galland L, Kabirian R, Guiu S, Poestch L, Deluche E, Cherifi F, Dalenc F, Volant E, Pistilli B, San T, Bachelot T, Patsouris A, Bocquet F, Bailleux C, Loirat D, Larrouquere L.   +25 more
europepmc   +1 more source

Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study. [PDF]

Breast Cancer Res Treat
Mayer EL, Collin SM, Hillman S, Berrocal-Almanza LC, Sparano J, Lam C.   +5 more
europepmc   +1 more source